US Drug Pricing Legislation Efforts Headed Toward Spring Renewal? A Look Ahead

US Senate drug pricing legislation that would impose price inflation rebates on drugs covered by Medicare and revise manufacturer discount obligations under the Part D benefit could find a vehicle for passage in a bill extending funding for high priority health care programs this May, according to Finance Committee Chairman Chuck Grassley, R-IA.

“We have until May 21 for some health care issues that have to be extended and that gives us the opportunity to get things like this done at that particular time,” Grassley told reporters in a recent briefing. Grassley and Finance Committee ranking member Ron Wyden, D-OR, are co-authors of the Prescription Drug Pricing Reduction Act